Predictive biomarkers in the management of EGFR mutant lung cancer

摘要: Activating mutations in the form of deletions exon 19 (del 19) or missense mutation L858R tyrosine kinase domain epidermal growth factor receptor (EGFR) predict outcome to use EGFR inhibitors (TKIs), such as gefitinib and erlotinib. Pooled data from several phase II studies show that erlotinib induce responses over 70% NSCLC patients harboring mutations, with progression-free survival (PFS) ranging 9 13 months. Two Caucasian Asian have confirmed these subgroups attain PFS up 14 These landmark outcomes been accompanied by new challenges, primarily additional role chemotherapy management tumors secondary T790M confers resistance TKIs. Mechanisms reversible TKIs should be further clarified could related modifications DNA repair.